Disease relevance of LY 53616

• The efficacy of frentizole in a murine model of lupus supports its usefulness as an immunoregulatory drug [1].
• The results of these series of experiments indicate that Frentizole, even at super immunosuppressive doses, does not predispose the hose (mice) to Pseudomonas aeruginosa, Candida albicans, herpes simplex virus, or Ann Arbor influenza virus [2].
• Although major toxicity has limited the utility of frentizole, its effect on the platelet counts of these thrombocytopenic patients is of interest [3].
• Frentizole therapy of thrombocytopenia in systemic lupus erythematosus and refractory idiopathic thrombocytopenic purpura [3].
• About half of the rats given 0.060 and 0.150% frentizole in the diet had lymphocytic thyroiditis [4].

High impact information on LY 53616

• Prolonged lifespans in female NZB/NZW mice treated with the experimental immunoregulatory drug frentizole [1].
• Autoimmune female New Zealand Black/New Zealand White mice were treated with frentizole, an experimental immunosuppressive drug [1].
• Frentizole in systemic lupus erythematosus. Current status [5].
• Eleven steroid-treated patients with active systemic lupus erythematosus received frentizole (150-350 mg/day) in combination with stable or decreasing doses of prednisone in an open label trial [6].
• Without serum, frentizole strongly enhanced phagocytosis, whereas lamprene, levamisole and dapsone had weaker enhancing activity [7].

Chemical compound and disease context of LY 53616

• However, there was no accelerated growth of murine sarcoma virus induced tumors or an SaI spindle cell fibrosarcoma during rather prolonged therapy with immunosuppressive doses of CPA, azathioprine or frentizole [8].

Biological context of LY 53616

• Analysis of the frentizole structure-activity relationship led to identification of a novel benzothiazole urea with a 30-fold improvement in potency [9].
• Data is presented comparing the activities of three immunosuppressive agents, cyclosphosphamide, frentizole and azathioprine in models of humoral immunity in mice [10].
• Comparative effects of azathioprine, cyclophosphamide and frentizole on cellular immunity in mice [8].
• In human lymphocytes, Frentizole inhibits the response to various phytomitogens without decreasing cell viability [11].

Anatomical context of LY 53616

• Frentizole was more effective in suppressing human lymphocytes responding to Con A and PWM, than it was in cells activated by PHA, specific antigen, or alloantigen [12].
• Normal mice treated with CPA showed a more drastic reduction in lymphoid elements of the spleen and thymus than mice treated with azathioprine or frentizole [8].
• In contrast to frentizole, both CPA and azathioprine were found to inhibit the proliferation of parental T-cells in a systemic GVHR [8].
• Cyclophosphamide and frentizole suppressed the primary and secondary plaque forming cell responses to sheep erythrocytes at lower doses than did azathioprine [10].

Associations of LY 53616 with other chemical compounds

• The in vitro effects of frentizole and methylprednisolone on human PBL were examined [12].

Analytical, diagnostic and therapeutic context of LY 53616

• Effect of frentizole on mitogen-induced blastogenesis in human lymphocytes [11].

References